| 0.8323 0.073 (9.61%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.11 | 1-year : | 1.28 |
| Resists | First : | 0.95 | Second : | 1.1 |
| Pivot price | 0.77 |
|||
| Supports | First : | 0.7 | Second : | 0.59 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.77 |
| MA(100) : | 0.89  |
MA(250) : | 1.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 7 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 2.45 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MIRA ] has closed below upper band by 25.6%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.83 - 0.83 | 0.83 - 0.84 |
| Low: | 0.76 - 0.77 | 0.77 - 0.77 |
| Close: | 0.81 - 0.81 | 0.81 - 0.82 |
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Thu, 17 Sep 2026
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review - Investing.com
Wed, 16 Sep 2026
63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - Stock Titan
Tue, 01 Sep 2026
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
Tue, 01 Sep 2026
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 42 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 30.5 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 211 (K) |
| Shares Short P.Month | 255 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -129.6 % |
| Return on Equity (ttm) | -217.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 4.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|